首页> 中文期刊> 《西部中医药》 >安神二号胶囊联合盐酸文拉法辛缓释片对焦虑障碍患者认知、社会功能的影响

安神二号胶囊联合盐酸文拉法辛缓释片对焦虑障碍患者认知、社会功能的影响

         

摘要

Objective: To evaluate the effects of A nShen capsule No.2 combined with venlafaxine hydrochloride sustained-release tablets on cognition and social function of patients with anxiety disorder. Method: All 180 patients, who met the standard of DSM- Ⅳ , were randomly divided into the treatment group and the control group, the observation time was eight weeks. Hamilton anxiety (HAMA), Hamilton depression scale (HAMD), Wisconsin card sorting test (WCST) and social disability screening schedule (SDSS) were taken as the tools to assess clinical effects. Result: By the end of 8th week, HAMA, HAMD and SDSS of both groups were lower than the baseline and the difference showed statistical meanings in improvements of WCST indexes except the numbers of persistent responses in the treatment group (P<0.01); the decrease of the treatment group was more significant than that of the control group in the score of HAMA and HAMD. Compared with the baseline, WSCT of the treatment group increased (-1.0±1.5), and the control group increased (-0.4±1.1); correct responses of the treatment group increased (-10.1 ±15.4), and the control group raised (-5.0±16.3); wrong responses of the treatment group declined (15.1 ±25.5) and the control group lowered (7.0±23.3); the conceptual level of the treatment group increased (-14.9±22.8), the control group raised (-9.2±26.3). The scale of SDSS in the treatment group decreased (6.1 ±4.3) and the control group lowered (4.5±3.6). Comparisons between both groups had differences and they showed statistical meaning (P<0.05). Conclusion: AnShen capsule No.2 combined with Venlafaxine hydrochloride sustained-release tablets are effective in improving anxiety disorder, cognition and social function in patients.%目的:探讨安神二号胶囊与盐酸文拉法辛对焦虑障碍认知及社会功能的影响.方法:将180 例符合DSM-Ⅳ标准的焦虑障碍患者随机分为治疗组和对照组各90 例,观察时间均为8 周.以HAMA、HAMD、WCST及社会功能SDSS 作为疗效评价工具.结果:治疗第8 周末,2 组HAMA、HAMD 及社会功能SDSS评分均较基线降低,WCST 指标中,除了治疗组持续应答数外均获改善,差异均有统计学意义(P<0.01);治疗组HAMA、HAMD 评分的降低较对照组更为明显.与基线比较,治疗组WCST 分类数较基线治疗组增加(-1.0±1.5),对照组增加(-0.4±1.1);正确应答数治疗组增加(-10.1±15.4),对照组增加(-5.0±16.3);错误应答数治疗组降低(15.1±25.5),对照组降低(7.0±23.3);概念化水平百分数治疗组增加(-14.9±22.8),对照组增加(-9.2±26.3).SDSS 评分较基线治疗组降低(6.1±4.3)分,对照组降低(4.5±3.6)分.组间上述各项比较,差异均有统计学意义(P<0.05).结论:安神二号胶囊配合盐酸文拉法辛治疗,对焦虑障碍患者的焦虑障碍、认知及社会功能的改善更为有效.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号